alpha-(4-isobutyl)phenyl-propionic acid | 1126652-03-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: alpha-(4-isobutyl)phenyl-propionic acid
• 英文别名: 2,4-dimethyl-2-phenyl-pentanoic acid；Isobutylphenyl propionic acid；2,4-dimethyl-2-phenylpentanoic acid
• CAS: 1126652-03-6
• 化学式: C₁₃H₁₈O₂
• 分子量: 206.285
• InChiKey: IAWWAVGUKRSONG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Kappa agonist compounds and pharmaceutical formulations thereof
  申请人：——

  公开号：US20030144272A1

  公开（公告）日：2003-07-31

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics are provided. The compounds of formulae I, II, IIA, III, IIIA, IIIB, IIIB-i, IV and IVA have the structure: 1 2 wherein R 1 , R 2 , R 3 , R 4 ; and X, X 4 , X 5 , X 7 , X 9 ; Y, Z and n are as described in the specification.

  提供具有kappa阿片受体激动剂活性的化合物，含有这些化合物的组合物以及使用它们作为镇痛剂的方法。 具有以下结构的化合物I、II、IIA、III、IIIA、IIIB、IIIB-i、IV和IVA： 1 2 其中 R 1 ，R 2 ，R 3 ，R 4 ；和 X，X 4 ，X 5 ，X 7 ，X 9 ； Y，Z和n如规范中所述。
• Mitochondria protecting agents for treating mitochondria associated diseases
  申请人：——

  公开号：US20020010195A1

  公开（公告）日：2002-01-24

  The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus, Parkinson's Disease, neuronal and cardiac ischemia, Huntington's disease and stroke.

  本发明总体上涉及用于治疗因线粒体功能障碍导致组织退化的疾病的线粒体保护剂，以及更具体地涉及与此相关的化合物、组合物和方法。本发明的方法包括向需要它的温血动物施用药物有效量的线粒体保护剂，本发明的组合物包含与药物可接受载体或稀释剂组合的线粒体保护剂。可以通过本发明治疗的线粒体相关疾病包括（但不限于）阿尔茨海默病、糖尿病、帕金森病、神经和心肌缺血、亨廷顿病和中风。
• PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II
  申请人：Dousson Cyril

  公开号：US20090060866A1

  公开（公告）日：2009-03-05

  Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formula I, II, III, I′, II′, I″, II″, Ia, IIa, or IIIa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本发明提供了磷二嗪聚合酶抑制剂，例如任何式I、II、III、I′、II′、I″、II″、Ia、IIa或IIIa的化合物，包含这些化合物的药物组合物，以及它们的制备方法。还提供了用于治疗宿主中HCV感染的方法。
• Colorant compounds
  申请人：Banning H. Jeffrey

  公开号：US20060020141A1

  公开（公告）日：2006-01-26

  Compounds of the formula wherein M is either (1) a metal ion having a positive charge of +y wherein y is an integer which is at least 2, said metal ion being capable of forming a compound with at least two chromogen moieties, or (2) a metal-containing moiety capable of forming a compound with at least two chromogen moieties, z is an integer representing the number of chromogen moieties associated with the metal and is at least 2, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , a, b, c, d, Y, and z are as defined herein, Q − is a COO − group or a SO 3 — group, A is an organic anion, and CA is either a hydrogen atom or a cation associated with all but one of the Q − groups.

  式中的化合物，其中M是一个带有正电荷+y的金属离子，其中y是至少为2的整数，该金属离子能够与至少两个色团基团形成化合物，或者M是一个含金属基团的基团，能够与至少两个色团基团形成化合物，z是表示与金属相关的色团基团数量的整数，至少为2，R1、R2、R3、R4、R5、R6、R7、a、b、c、d、Y和z的定义如上所述，Q-是一个COO-基团或SO3-基团，A是一个有机阴离子，CA是一个氢原子或与除一个Q-基团之外的所有Q-基团相关联的阳离子。
• Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith
  申请人：——

  公开号：US20040220112A1

  公开（公告）日：2004-11-04

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics and pruritic agents are provided. The compounds of formulae I, II, III and IV have the structure: 1 wherein X, X 4 , X 5 , X 7 , X 9 ; R 1 , R 2 , R 3 , R 4 ; and Y, Z and n are as described in the specification

  提供具有kappa阿片受体激动剂活性的化合物、包含它们的组合物和使用它们作为镇痛剂和止痒剂的方法。公式I、II、III和IV的化合物具有以下结构：1其中X、X4、X5、X7、X9；R1、R2、R3、R4；以及Y、Z和n的描述如规范中所述。